Still SF [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2016-10-07 10:38 (2087 d 16:48 ago) – Posting: # 16704
Views: 11,819

Hi VStus,

lucid words about SF and great ideas about hacking embeded Linux-machines. :-D

I think that TSDs for reference-scaling are not so important compared to ABE. Let us consider two scenarios.
  1. CV higher than expected.
    • ABE
      • In a fixed sample design we loose power.
      • In a TSD with sample size re-estimation we proceed to the second stage and preserve power.
    • RSABE or ABEL
      The acceptance range is scaled and power is maintained.
  2. CV lower than expected.
    • ABE
      • In a fixed sample design we gain power.
      • In a TSD we have some chances to demonstrate BE already in the first stage. Hence, my personal recommendation for n1 75-80% of the fixed sample’s n.
    • RSABE or ABEL
      We loose power until we reach CVwR. Then power increases.

To summarize: In reference-scaling we have to consider lower CVs only. However, the potential impact is over-rated by many. What really hurts (in all designs) is a too optimistic assumption of the GMR.

Dif-tor heh smusma 🖖 [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
22,167 posts in 4,645 threads, 1,572 registered users;
online 9 (0 registered, 9 guests [including 3 identified bots]).
Forum time: Sunday 03:27 CEST (Europe/Vienna)

The person interested in success has to learn
to view failure as a healthy, inevitable part
of the process of getting to the top.    Joyce Brothers

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz